Hi again :)

I found this document that i wants to share with you, this is an investor friendly guide to investing in gene therapy from October 2017, one can only be impressed by the Potential and added value of our FimaNAc program:
Link http://www.fullertreacymoney.com/system/data/files/PDFs/2017/October/12th/rj%20on%20genetics.pdf

PAGE 3:
Talks about market potential for Gene Therapy, it is huge!!
“By our count, there are at least 33 public and 27 private companies developing gene therapy products either by themselves or through partnerships (Exhibits 2 and 3). Collectively, these players are working on one-time solutions for at least 59 diseases, addressing $100+ billion market opportunities, according to our estimates. Given the number of players, the compelling clinical results achieved to date, and the partnerships/deals done in the space, we believe gene therapy is poised to become the next-wave therapeutic category. If we are correct, the current setup of this space is very similar to that seen in the CAR T space, where we just witnessed one of the largest acquisitions of a pre-commercial company (Gilead’s acquisition of Kite for $12 billion) ever”

PAGE 4:
Talks about Gene Therapy Valuation, impressive rate of development
“Arguably, the entire gene therapy space has taken off like a rocket, with the total market capitalization of the companies in our gene therapy index growing from $9.7 billion as of January 1, 2017, to $20.3 billion as of October 6, 2017. Specifically, the gene therapy group generated an average return of approximately 90% year-to-date, outperforming both the NBI (28%) and the S&P500 (14%) (Exhibit 27). Sangamo Therapeutics achieved the highest return of 423%, while Applied Genetic Technologies Corporation (AGTC) was the worst performer so far”

PAGE 21:
Talks about AAV vector as a delivery vehicle that we discussed in this thread earlier:
“AAV vectors are one of the most favorable delivery vehicles for gene therapy largely due to two reasons: 1) the AAV genome contains no expressed genes; therefore, induction of host immunity against the vector is less problematic as compared to adenoviral vectors, except for induction of antibodies that are directed against the AAV capsid (as it flows through the blood stream); and 2) the genomic integration of recombinant AAV vectors occurs at a very low background frequency (0.1 - 0.5%), therefore minimizing the insertional mutagenesis risk with no reported genotoxicity to date"

PAGE 9:
The table shows explicitly that most of the top 10 Big Pharma are using the AAV delivery vehicle for their clinical programs including Pfizer, Bayer, Bristol-Myers Squibb Sanofi …etc and of course we can add to them Astra Zeneca with their latest clinical collaboration with 4D Molecular Therapeutics that we discussed earlier.

My conclusion:
With FimaNAc we are not just sitting on Gold (may be on Rhodium ?). Based on PCI presentation FimaNAc can SUCESSFULLY deliver AAV vector delivery vehicle, which is the most popular for gene therapy's on-going clinical programs. I believe with Pci Biotech strategy to out-license FimaNAc on SEMI-NON exclusive basis gives us the chance to work and collaborate with more and more companies out their including MANY of the top 10 big pharma. The potential for this is HUGE that I can not see where it ends.
Just imagine that FimaNAc would be the KEY for gene therapy efficient delivery where gene therapy business potential is worth 100 billion USD.